← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems
biapenem
J01DH05
Forms & Strengths
- Injectable powder: 300 mg per vial
- Injectable powder: 600 mg per vial
Adult Dosing
- Complicated intra-abdominal infections: 300 mg to 600 mg IV every 12 hours
- Lower respiratory tract infections: 300 mg to 600 mg IV every 12 hours
- Urinary tract infections: 300 mg to 600 mg IV every 12 hours
- Infusion duration: Administer intravenously over 30 to 60 minutes
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been firmly established; use generally not recommended or restricted based on institutional protocols
Indications
- Complicated intra-abdominal infections
- Lower respiratory tract infections
- Complicated urinary tract infections
- Infections caused by susceptible gram-positive, gram-negative, and anaerobic aerobic bacteria
Mechanism of Action
- Carbapenem antibacterial agent
- Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)
- Exhibits high stability against hydrolyzing action by most beta-lactamases
Contraindications
- Known hypersensitivity to biapenem or other carbapenem class antibiotics
- History of severe hypersensitivity reactions (e.g., anaphylaxis) to beta-lactams
Adverse Reactions
- Diarrhea
- Nausea and vomiting
- Rash
- Elevated liver transaminases (ALT, AST)
- Injection site reactions
- Seizures (rare, typical of carbapenem class)
Drug Interactions
- Valproic acid: Concomitant use may significantly decrease valproic acid serum concentrations, leading to loss of seizure control
- Probenecid: Inhibits renal tubular secretion of biapenem, potentially increasing its plasma concentrations and half-life
Curated Content: Needs Vetting Before Put to Clinical Use